$SNGX

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.

Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.

Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.

Soligenix's dusquetide (SGX945) receives EU orphan drug designation for Behçet's Disease, backed by Phase 2a data showing 40% ulcer reduction with no adverse events.

Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.